Phase I/II study to evaluate the safety and immunogenicity of MG1109 in healthy adult volunteers
Not Applicable
Recruiting
- Conditions
- Diseases of th respiratory system
- Registration Number
- KCT0000119
- Lead Sponsor
- Koera University Guro Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 346
Inclusion Criteria
Healthy adults who are available for follow-up during the study
Exclusion Criteria
1. Subjects with history of exposure to the H5N1 subtype or H5N1 subtype vaccine
2. Subjects with immune system disorder including immune deficiency disease
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms drive MG1109's immune activation against H5N1 in healthy adults?
How does MG1109's immunogenicity compare to standard H5N1 vaccines like Flublok or Novartis' formulations?
Which biomarkers correlate with robust antibody titers or T-cell responses to MG1109 in pre-pandemic trials?
What are the common adverse events of MG1109 and their management strategies in Phase I/II trials?
Are there combination therapies or alternative platforms (e.g., cell-based) for H5N1 vaccines similar to MG1109?